Claims for Patent: 8,039,504

Summary for Patent: 8,039,504

Title:	Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Abstract:	Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.
Inventor(s):	Jordan; Robert F. (Corvallis, OR), Bailey; Thomas R. (Phoenixville, PA), Rippin; Susan R. (Wilmington, DE), Dai; Dongcheng (Corvallis, OR)
Assignee:	Siga Technologies, Inc. (New York, NY)
Application Number:	11/785,998
Patent Claims:	1. A composition comprising a compound and one or more additional ingredients selected from the group consisting of a water-insoluble diluent, a water-soluble diluent, a disintegrant, a binder, a wetting agent, a solubilizer, a glidant, a lubricant, and a granulating solvent, wherein said compound is selected from the group consisting of: 4-Trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocy- -cloprop[f]isoindol-2(1H)-yl)-benzamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol- -2(1H)-yl)-4-pyridinecarboxamide; 4-Bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]- -isoindol-2(1H)-yl)-benzamide; 3-Bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]- -isoindol-2(1H)-yl)-benzamide; 3-Chloro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f- -]isoindol-2(1H)-yl)-benzamide; 2-Bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]- -isoindol-2(1H)-yl)-benzamide; 2-Chloro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f- -]isoindol-2(1H)-yl)-benzamide; 4-Chloro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f- -]isoindol-2(1H)-yl)-benzamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol- -2(1H)-yl)-3-pyridinecarboxamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol- -2(1H)-yl)-2-pyridinecarboxamide; 4-Methoxy-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[- -f]isoindol-2(1H)-yl)-benzamide; 4-Nitro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]- -isoindol-2(1H)-yl)-benzamide; 4-Fluoro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f- -]isoindol-2(1H)-yl)-benzamide; 3-Fluoro-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f- -]isoindol-2(1H)-yl)-benzamide; 4-Bromo-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethanocycloprop[f]- -isoindol-2(1H)-yl)-benzamide; 4-Bromo-N-(1,3-(2H,3aH)-dioxo-4,8-ethenocyclohepta[c]pyrrolyl)-benzamide; 4-Bromo-N-(octahydro-1,3-dioxo-2H-isoindol-2-yl)-benzamide; 4-Bromo-N-bicyclo[2.2.2]oct-5-ene-2,3-dicarboximido-benzamide; 4-Bromo-N-bicyclo[2.2.2]octane-2,3-dicarboximido-benzamide; 4-Cyano-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethanocycloprop[f]- -isoindol-2(1H)-yl)-benzamide; 4-Trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethanocy- -cloprop[f]isoindol-2(1H)-yl)-benzamide; 4-Methyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f- -]isoindol-2(1H)-yl)-benzamide; 3-Bromo-N-(1',3',3'a,4',7',7'a-hexahydro-1',3'-dioxospiro[cyclopropane-1,- -8'-[4,7]methano[2H]isoindol]-2'-yl)-benzamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol- -2(1H)-yl)-tricyclo[3.3.1.13,7]decane-1-carboxamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol- -2(1H)-yl)-benzeneacetamide; 4-Bromo-N-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol-2-yl- -)-benzamide; 2,4-Dichloro-N-(1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2H-isoindol- -2-yl)-benzamide; 4-Trifluoromethyl-N-bicyclo[2.2.2]oct-5-ene-2,3-dicarboximido-benzamide; 4-Trifluoromethyl-N-bicyclo[2.2.2]octane-2,3-dicarboximido-benzamide; 4-Trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocy- cloprop[f]isoindol-2(1H)-yl)-N-methylbenzamide; 4-Trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocy- cloprop[f]isoindol-2(1H)-yl)-N-ethylbenzamide; 4-Trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-7,8-dimethyl- -4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide; 4-Trifluoromethyl-N-(3a,4,7,7a-tetrahydro-4,7-etheno-1H-isoindol-2(1H)-yl- )-benzamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-7,8-dimethyl-4,6-ethenocyclopr- op[f]isoindol-2(1H)-yl)-acetamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-7,8-dimethyl-4,6-ethenocyclopr- op[f]isoindol-2(1H)-yl)-but-3-enamide; N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-7,8-dimethyl-4,6-ethenocyclopr- op[f]isoindol-2(1H)-yl)-cyclohexanecarboxamide; 4-Trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-7,8-dimethyl- -4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzylacetamide; 4-Pyridyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-7,8-dimethyl-4,6-eth- enocycloprop[f]isoindol-2(1H)-yl)-acetamide; 3-Thienyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-7,8-dimethyl-4,6-eth- enocycloprop[f]isoindol-2(1H)-yl)acetamide; 4 (Trifluoromethyl)-N-[(3aR,4S,4aS,5aR,6R,6aS)-3,3a,4,4a,5,5a,6,6a-octahydr- o-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-benzamide; and 2,4-Dimethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocyclopr- op[f]isoindol-2(1H)-yl)-thiazole-5-carboxamide or a pharmaceutically acceptable salt thereof. 2. A composition according to claim 1, wherein said compound is 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocy- cloprop[f]isoindol-2(1H)-yl)benzamide. 3. A composition according to claim 1, wherein the water-insoluble diluent is microcrystalline cellulose. 4. A composition according to claim 1, wherein the water-soluble diluent is lactose monohydrate. 5. A composition according to claim 1, wherein the disintegrant is croscarmellose sodium. 6. A composition according to claim 1, wherein the binder is hydroxypropylmethyl cellulose. 7. A composition according to claim 1, wherein the glidant is colloidal silicone dioxide. 8. A composition according to claim 1, wherein the lubricant is magnesium stearate. 9. A composition according to claim 1, wherein the granulating solvent is water. 10. An oral pharmaceutical composition according to claim 1. 11. The pharmaceutical composition of claim 1 in the form of a capsule. 12. The pharmaceutical composition of claim 1 comprising about 25 or 200 mg of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-th- enocycloprop[f]isoindol-2(1H)-yl)benzamide. 13. A unit dosage form for oral administration comprising: (a) about 25.00 mg of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-thenocyc- loprop[f]isoindol-2(1H)-yl)benzamide; (b) about 119.0 mg of lactose monohydrate; (c) about 38.5 mg of croscarmellose sodium; (d) about 1.75 mg of colloidal silicon dioxide; (e) about 12.25 mg of hydroxypropoyl methylcellulose; (f) about 7.0 mg of sodium lauryl sulfate; (g) about 1.75 mg of magnesium stearate; and (h) a quantity of microcrystalline cellulose up to about 144.76 mg such that the total weight of the dosage form is about 350 mg. 14. A unit dosage form for oral administration comprising: (a) about 200.00 mg of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-thenocyc- loprop[f]isoindol-2(1H)-yl)benzamide; (b) about 33.15 mg of lactose monohydrate; (c) 42.90 mg of croscarmellose sodium (d) about 1.95 mg of colloidal silicon dioxide; (e) about 13.65 mg of hydroxypropoyl methylcellulose (f) about 7.80 mg of sodium lauryl sulfate; (g) about 1.95 mg of magnesium stearate; and (h) a quantity of microcrystalline cellulose up to about 88.60 mg such that the total weight of the dosage form is about 390 mg.